 Sparse-fur (spf) mutant mice X-linked ornithine transcarbamylase deficiency used study effect L-carnitine energy metabolites congenital hyperammonemia. L-Carnitine used doses 2, 4, 8, 16 mmol/kg body weight (BW), levels ammonia, glutamine, glutamate, intermediates energy metabolism measured brain liver spf/Y mice. Cerebral hepatic levels ammonia decreased 4 mmol L-carnitine (P < .001), whereas doses seem effect metabolite. Cerebral levels glutamine decreased following administration L-carnitine doses 4 mmol/kg BW, whereas hepatic glutamine levels remained unaltered doses L-carnitine. cerebral hepatic levels pyruvate, lactate, alpha-ketoglutarate decreased doses 8 mmol L-carnitine/kg BW. L-Carnitine treatment elevated adenosine triphosphate (ATP), free coenzyme (CoA), acetyl CoA levels brain liver spf/Y mice. Cytosolic mitochondrial redox ratios spf/Y mice, altered congenital chronic hyperammonemia, partially corrected L-carnitine administration. L-Carnitine supplementation spf/Y mice sodium benzoate therapy also restored availability free CoA ATP, thus counteracting adverse effects higher doses sodium benzoate. changes free CoA acetyl CoA levels could due deinhibition pantothenate kinase stimulation fatty acid oxidation L-carnitine.(ABSTRACT TRUNCATED 250 WORDS)